-+ 0.00%
-+ 0.00%
-+ 0.00%

Hengrui Pharmaceutical (01276): HRS-2329 tablets, HRS 6093 tablets, SHR-9839 (sc) for injection, HRS-4642 injections, and adbelizumab injections obtained drug clinical trial approval notices

Zhitongcaijing·11/18/2026 09:33:06
Listen to the news

Zhitong Finance App News, Hengrui Pharmaceutical (01276) issued an announcement. Recently, Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”) and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue the “Drug Clinical Trial Approval Notice” for HRS-2329 tablets, HRS 6093 tablets, injectable SHR-9839 (sc), HRS-4642 injections, and adbelimab injections “Book”. Clinical trials will be carried out in the near future.